Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT03875235Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Primary completion
- Aug 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of durvalumab in biliary tract cancer (BTC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Overall Survival at 27 months and Overall Survival Rate at 18 months. Started Apr 2019; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03875235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875235.